GSK plc (NYSE:GSK) has announced its plans to spend £1 billion over the next ten years on R&D focused on infectious diseases that disproportionately affect lower-income countries. Diseases covered in the research will include malaria, tuberculosis, HIV, neglected tropical diseases (NTDs) and antimicrobial resistance (AMR). The HIV focus will be through ViiV Healthcare, a joint…
Gilead to pay $1.25B in settlement with ViiV Healthcare
Gilead Sciences (NSDQ:GILD) will pay a 3% royalty on future U.S. sales of Biktarvy on top of a $1.25 billion upfront payment to settle global patent infringement litigation with ViiV Healthcare. The royalty payments will be in effect until the expiration of the applicable patent (No. 8,129,385) on 5 October 2027. Biktarvy generated $7.26 billion…